Discover a groundbreaking webinar delving into an (artificial intelligence) AI-based, multi-domain digital biomarker platform in neurology and neuropsychiatry clinical trials and patient care. To date, the lack of objective measures in central nervous system (CNS) clinical studies has resulted in less than 6% of drugs in this space making it to market. Many of the validated cognitive assessments today are paper-based, introducing the potential for bias and limiting ethnic and geographic diversity in clinical studies. An additional challenge facing CNS studies is the higher-than-average patient drop-out rates, in large part due to the burden associated with attending clinical site visits.
What if a team could capture objective physiological and behavioral study data from a diverse group of patients on an ongoing basis without them having to leave the comfort of their own homes? Could researchers escalate the discovery of the next breakthrough treatment by streamlining the study timelines and costs?
Designed to provide an industry-wide standard for real-world measurement of disease progression, Cumulus combines patented technology, in-house expertise and key industry partnerships to capture large amounts of real-world, clinical data repeated over time, across multiple behavioral and physiological domains in the patient’s home — all with an electroencephalogram (EEG) headset synced to a novel, tablet-based neuro-assessment platform. Together with machine learning (ML) analytics and the world’s largest database of annotated, longitudinal, neurofunctional data, Cumulus simplifies and improves the robustness of neuroscience clinical trials to provide the best and most cost-effective assessment of CNS treatment outcomes.
Join Brian Murphy, PhD, Co-Founder and Chief Scientific Officer of Cumulus Neuroscience and CJ Barnum, PhD, VP of CNS Development at INmune Bio to learn how his team is leveraging the Cumulus Neuroassessment Platform to advance novel CNS therapeutics.
Brian Murphy, PhD, co-founder and Chief Scientific Officer, Cumulus Neuroscience
Brian Murphy, PhD is co-founder and Chief Scientific Officer of Cumulus Neuroscience. He is a computational neuroscientist who is an expert in brain-reading technology, using machine learning methods to decode brain states from EEG, fMRI and MEG. His academic career a faculty position at Queen’s University Belfast, senior researcher at Carnegie Mellon University’s Department of Machine Learning and as a post-doc at the Centre for Mind/Brain Sciences, University of Trento in Italy. He has a PhD in Cognitive Science from Trinity College Dublin, is a member of the Alzheimer’s Association EEG PIA committee and organized the MLINI series of workshops on machine learning with neuroimaging data at NeurIPS.
CJ Barnum, PhD, VP of CNS Development, INmune Bio, Inc.
CJ Barnum, PhD is the VP of CNS Development at INmune Bio, Inc. He is a neuroimmunologist with broad expertise across neurodegenerative and psychiatric diseases holding multiple positions in academia and industry, including Emory University, FPRT Bio., SonosBio and most recently Takeda Pharmaceuticals. His focus has been on translating inflammatory therapies into clinical treatments for neurologic diseases using a biomarker-directed approach. Dr.Barnum has been working with XPro1595 for more than a decade, first at Emory University with Dr. Malú Tansey and subsequently as a consultant for FPRT Bio., Inc. and INmune Bio, before joining INmune Bio full time in 2018. Dr. Barnum’s research has been supported by NIH, The Michael J Fox Foundation and the Alzheimer’s Association. He received his PhD in Neuroscience from Binghamton University.
Who Should Attend?
This webinar will appeal to professionals focused on diseases in the CNS space in the following fields:
- Biopharma clinical operations
- Clinical R&D
- Medical affairs
What You Will Learn
Attendees will gain insights into:
- How digital biomarkers have the potential to transform the CNS space much the same way that next-generation sequencing has transformed oncology, enabling personalized treatment
- The power of longitudinal EEG data synchronized with behavioral assessment data and how this can accelerate clinical studies, saving time and budget
With a mission to generate the data and insights required to accelerate diagnosis and management of central nervous system (CNS) disorders for millions of patients and caregivers around the world, Cumulus Neuroscience is advancing an AI-based, multi-domain digital biomarker platform to enable better, faster decision making in neurology and neuropsychiatry clinical trials and patient care. Designed for and with 10 of the world’s leading pharma companies, the platform enables decentralized trials, and is already making a difference in the development of therapies for Alzheimer’s Disease, depression and schizophrenia.